AstraZeneca AZN shares gained 1% to $34.04, after the company landed its third deal in less than a week aimed at bolstering its cancer drug pipeline by signing up rights to an experimental immunotherapy from Inovio Pharmaceuticals. Share volume was 224,000, compared to an all-day average of 522,000
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
